Obesity rates for Black children and adolescents are 22.4% in the decade before the pandemic and 35% in the 2 years after the ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Dr Amal Mattu breaks down the key updates — and lingering pitfalls — in the 2025 ACS guidelines that every acute care ...

Daily medicines shortages are leaving patients at risk and pharmacists overwhelmed, a survey by Community Pharmacy England showed.

Vaccine hesitancy is understandable given the number and nature of early-childhood immunizations. Clinicians should ...

Lorundrostat, an aldosterone synthase inhibitor, effectively treated uncontrolled hypertension in Launch-HTN, researchers ...

Brad Spellberg, MD, urges rethinking the ‘finish the course’ dogma for antibiotics: Extra days may do more harm than good.

A novel predictive model named STAYHOME effectively estimated the risk of losing the ability to live at home among older ...

A tight control treatment with golimumab in early, active axial spondyloarthritis induces high rates of sustained clinical ...

New data suggest mid/distal esophageal coin retention in kids often resolves without intervention — prompting reconsideration ...

Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...